Literature DB >> 6285744

Effects of percutaneous estradiol and conjugated estrogens on the level of plasma proteins and triglycerides in postmenopausal women.

F Elkik, A Gompel, C Mercier-Bodard, F Kuttenn, P N Guyenne, P Corvol, P Mauvais-Jarvis.   

Abstract

Percutaneous administration of estradiol (E2) is a new substitutive treatment for postmenopausal women. In order to compare hepatic action of percutaneous E2 with that of conjugated estrogens, 18 postmenopausal women were allocated at random to receive one of these two types of natural estrogens for 21 days. Eight patients (group I) received conjugated estrogens orally, 1.25 mg daily. Ten patients (group II) were told to apply percutaneous E2 ointment, 5 gm (i.e., 3 mg of E2), each evening on the abdominal skin. E2, estrone (E1), follicle-stimulating hormone (FSH), and luteinizing hormone (LH), and several markers of estrogen action were evaluated before and after treatment. Both types of treatment were biologically effective, as indicated by the decrease in plasma gonadotropins and the increase in estrogen levels. However, conjugated estrogens produced a greater increase in E1 than in E2; hence, the E2/E1 ratio was 0.57 in group I, whereas it was approximately 1 in group II. Plasma renin substrate increased significantly (by 180%) in group I but not in group II. In the same way, conjugated estrogens produced a modest (12%) but significant decrease in antithrombin III, whereas there was no variation with percutaneous E2. Sex steroid-binding protein was the most sensitive parameter for the hepatic action of estrogen, and increased by 18.66% with percutaneous E2 and by 150% with conjugated estrogens. Plasma triglycerides tended to increase in group I and to decrease in group II, but not significantly. Therefore, percutaneous administration of of E2, in contrast to conjugated estrogens, can produce plasma levels of estrogens closer to those observed in the follicular phase and less alterations in protein synthesis. This lesser toxicity may be explained partially by the route of administration, since with percutaneous administration of E2, the steroid bypasses the liver.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6285744     DOI: 10.1016/0002-9378(82)90468-9

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  7 in total

1.  Associations between circulating components of the renin-angiotensin-aldosterone system and left ventricular mass.

Authors:  H Schunkert; H W Hense; M Muscholl; A Luchner; S Kürzinger; A H Danser; G A Riegger
Journal:  Heart       Date:  1997-01       Impact factor: 5.994

2.  Impact of 17β-estradiol on complex I kinetics and H2O2 production in liver and skeletal muscle mitochondria.

Authors:  Maria J Torres; Terence E Ryan; Chien-Te Lin; Tonya N Zeczycki; P Darrell Neufer
Journal:  J Biol Chem       Date:  2018-09-14       Impact factor: 5.157

3.  Cyclic hormonal replacement therapy after the menopause: transdermal versus oral treatment.

Authors:  M Cortellaro; T Nencioni; C Boschetti; S Ortolani; F Buzzi; B Francucci; M P Caraceni; P Abelli; F Polvani; C Zanussi
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 4.  Menopausal Hormone Therapy and Type 2 Diabetes Prevention: Evidence, Mechanisms, and Clinical Implications.

Authors:  Franck Mauvais-Jarvis; JoAnn E Manson; John C Stevenson; Vivian A Fonseca
Journal:  Endocr Rev       Date:  2017-06-01       Impact factor: 19.871

5.  Stimulation of breast cancer cells in vitro by the environmental estrogen enterolactone and the phytoestrogen equol.

Authors:  W V Welshons; C S Murphy; R Koch; G Calaf; V C Jordan
Journal:  Breast Cancer Res Treat       Date:  1987-11       Impact factor: 4.872

Review 6.  The role of estrogens in control of energy balance and glucose homeostasis.

Authors:  Franck Mauvais-Jarvis; Deborah J Clegg; Andrea L Hevener
Journal:  Endocr Rev       Date:  2013-03-04       Impact factor: 19.871

7.  Type 2 Diabetes Mellitus and Menopausal Hormone Therapy: An Update.

Authors:  Stavroula A Paschou; Nikolaos Papanas
Journal:  Diabetes Ther       Date:  2019-09-24       Impact factor: 2.945

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.